BMRN — Biomarin Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- $16.16bn
- $16.03bn
- $2.42bn
- 88
- 18
- 92
- 72
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,704 | 1,860 | 1,846 | 2,096 | 2,419 |
Cost of Revenue | |||||
Gross Profit | 1,345 | 1,336 | 1,376 | 1,612 | 1,904 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,805 | 1,897 | 1,929 | 1,946 | 2,286 |
Operating Profit | -100 | -36.8 | -82.3 | 150 | 134 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -94.8 | -42.3 | -75.3 | 150 | 189 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.8 | 4.56 | -68 | 123 | 168 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -23.8 | 859 | -64.1 | 142 | 168 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.8 | 859 | -64.1 | 142 | 168 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.224 | -0.178 | -0.372 | 0.281 | 0.989 |